Dr. Alexander Drilon, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
13 drugs studied
Area of expertise
1Lung Cancer
Stage IV
RET positive
Stage III
2Non-Small Cell Lung Cancer
RET positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Alexander Drilon, MD is currently running
Lorlatinib + Ramucirumab
for Lung Cancer
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
Recruiting1 award Phase 1 & 213 criteria
NVL-655
for NSCLC
This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.
Recruiting1 award Phase 1 & 27 criteria
More about Alexander Drilon, MD
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Alexander Drilon, MD has experience with
- Cabozantinib
- Repotrectinib (TPX-0005)
- ELU001
- TPX-0046
- NVL-655
- NVL-520
Breakdown of trials Alexander Drilon, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Solid Tumors
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander Drilon, MD specialize in?
Alexander Drilon, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are RET positive.
Is Alexander Drilon, MD currently recruiting for clinical trials?
Yes, Alexander Drilon, MD is currently recruiting for 5 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Alexander Drilon, MD has studied deeply?
Yes, Alexander Drilon, MD has studied treatments such as Cabozantinib, Repotrectinib (TPX-0005), ELU001.
What is the best way to schedule an appointment with Alexander Drilon, MD?
Apply for one of the trials that Alexander Drilon, MD is conducting.
What is the office address of Alexander Drilon, MD?
The office of Alexander Drilon, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.